CliffBio
biologic

Veopoz

pozelimab-bbfg

Loss of exclusivityAugust 2035projected — 12-year biologic exclusivity estimate
CompanyRegeneron Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameVeopoz
Active ingredientpozelimab-bbfg
Strength400MG/2ML (200MG/ML)
Dosage formInjection
RouteIntravenous, Subcutaneous
ModalityBiologic
FDA approvalAugust 2023
Marketing statusRx

More from Regeneron Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Veopoz patent cliff — loss of exclusivity August 2035 | CliffBio